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Summary The relationship between mammalian facilitative glucose transport proteins (GLUT) and multidrug resistance was examined in two
vincristine (VCR)-selected murine erythroleukaemia (MEL) PC4 cell lines. GLUT proteins, GLUT1 and GLUT3, were constitutively co-
expressed in the parental cell line and also in the VCR-selected cell lines. Increased expression of the GLUT1 isoform was noted both in the
PC-V40 (a non-P-glycoprotein, mrp-overexpressing subline) and in the more resistant PC-V160 (overexpressing mrp and mdr3) cell lines.
Overexpression of GLUT3 was detected only in the PC-V160 subline. An increased rate of facilitative glucose transport (Vmu) and level of
plasma membrane GLUT protein expression paralleled increased VCR resistance, active VCR efflux and decreased VCR steady-state
accumulation in these cell lines. Glucose transport inhibitors (GTIs), cytochalasin B (CB) and phloretin blocked the active efflux and
decreased steady-state accumulation of VCR in the PC-V40 subline. GTIs did not significantly affect VCR accumulation in the parental or PC-
V160 cells. A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP,
which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a
similar hydropathy plot pattern. The findings suggested that CB bound to MRP and directly or indirectly lowered VCR efflux and/or CB bound
to one or both GLUT proteins, which acted to lower the VCR efflux mediated by MRP. This is the first report of a non-neuronal murine cell line
that expressed GLUT3.
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Mechanisms associated with the development of MDR are often
energy-dependent processes, which involve membrane transport
(Juranka et al, 1989; Gottesman, 1993; Gottesman and Pastan,
1993) and detoxification of drugs (Tew, 1994). This adaptation to
MDR may involve additional energy requirements (Haspel et al,
1986; Fanciulli et al, 1993). For example, alterations in glucose
metabolism are associated with drug resistance in tumour cell
lines. One characteristic of malignant cells is an increased rate of
oxidative glycolysis and a preferential utilization of oxidative
phosphorylation to synthesize ATP (Lyon et al, 1988).
Much ofthe energy demands are metby glucose transport across
the plasma membrane ofmammalian cells, mediated by afamily of
facilitative glucose transporters (GLUT1-4) (Kahn and Flier,
1990; Bell et al, 1993). These exhibit a tissue-specific pattern of
expression and distinct kinetic and regulatory properties (Pessin
and Bell, 1992). The diversity of the isoforms allows for the regu-
lation of intracellular glucose levels over a range of physiological
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conditions. GLUT1 is abundantly expressed in erythroid cells;
GLUT3 is the primary transporter ofglucose in neurons (Bell et al,
1990, 1993). GLUT1 and GLUT3 are considered to be responsible
for basal glucose transport in mammalian cells and are localized
primarily in the plasma membrane (Asano et al, 1992; Pessin and
Bell, 1992). Facilitative glucose transport is anenergy-independent
saturable process using an alternating conformational model of
sugar transport (Walmsley, 1988).
A possible role for the glucose transporter in the modulation of
multidrug resistance (MDR) was suggested (Vera et al, 1991).
These investigators found that glucose transport inhibitors (GTIs)
increased VCR accumulation in Xenopus oocytes transfected with
GLUTI mRNA. The effect of GTIs on VCR transport in a MDR
cell line also suggested a role for GLUT proteins in VCR trans-
port. We examined the effect of GTIs on vincristine transport in
drug-resistant MEL cell lines, which coexpressd GLUT1 and
GLUT3 and overexpressed the multidrug resistance-associated
protein (MRP) and/or P-glycoprotein (P-gp).
MATERIALS AND METHODS
Cell lines
The murine erythroleukaemia (MEL) cell line PC4 and the vin-
cristine (VCR)-selected drug-resistant sublines, named according
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to the highest drug concentration (ng ml-') into which they were
passaged, have been described previously (Slapak et al, 1994). The
PC-V40 subline was 42-fold more resistant and PC-V160 was
215-fold more resistant to VCR than the parental cell line. Both
sublines demonstrated energy-dependent VCR efflux and overex-
pressed the multidrug resistance-associated protein (MRP) (Slapak
et al, 1996); only PC-V160 cells overexpressed P-glycoprotein
(Slapak et al, 1994). Another MEL cell line, C7D (Slapak et al,
1990), and AUXB1 cells (Maher et al, 1992), an auxotrophic CHO
cell line (provided by V Ling, Ontario Cancer Institute, Toronto,
Canada), were used as controls for GLUTI and GLUT3 identifica-
tion in membrane preparations. Cells were grown in Eagle's basal
medium (PC4 and C7D) or minimal essential media (AUXB1)
supplemented with 10% heat-inactivated fetal calf serum in a 5%
carbon dioxide atmosphere (Revco 2000, Ashville, NC, USA).
Evaluation of steady-state glucose transport
Steady-state glucose transport was measured as a function of the
uptake ofthe glucose analogue 2-deoxy-D-glucose (dGlc) at 50gM
(Asano et al, 1991) in phosphate-buffered saline (PBS) during a
60-min incubation at 37°C. This analogue is not metabolized by
mammalian cells beyond the initial phosphorylation step by hexo-
kinase. At this concentration, dGlc presumably represents steady-
state glucose levels (Renner et al, 1972). Cells (1 x 106 ml' were
preincubated either in the presence of 100 gM phloretin/PBS or
PBS alone for 15 min at 37°C. Prior to an additional 60 min, 50gM
dGlc and 5 gCi ml-' (0.096 JM) 2-deoxy-D-[2,6- 3H]glucose (52 Ci
mmol-'; Dupont New England Nuclear, Boston, MA, USA) were
added. The reactions were terminated by centrifugation (3 min at
10 000 x g) of 200-,ul samples (2 x I05 cells) through silicone oil
in microfuge tubes previously prepared with 20 gl of formic
acid overlaid with 200 ,ul of silicone oil (D = 1.035-1.045; Nye
Lubricants, New Bedford, MA, USA). After freezing the tubes, the
tips were severed (containing the frozen formic acid/cell pellet) and
the cell-associated radioactivity was determined by scintillation
counting (Slapak et al, 1996). The data are expressed as a percent-
age of cell-associated [3H]dGlc in parental cells after 60 min of
incubation from six experiments each performed in duplicate.
Kinetics of glucose transport
Cells were washed extensively in PBS and resuspended to 1 x 106
ml-' in PBS at 37°C. 2-deoxy-D-[2,6-3H] glucose ([3H]dGlc)(52 Ci
mmol-'; Dupont New England Nuclear, Boston, MA, USA) was
added (1.6 ,uCi ml-') to a final concentration of 0.2-2 mm dGlc.
Over a 5-min interval, the uptake of [3H]dGlc increased linearly
with time for each subline. Therefore, uptake, and not phosphory-
lation, was the main determinant in cellular dGlc accumulation
(Colville et al, 1993). Cell-associated radioactivity was deter-
mined after centrifugation of samples (2 x 105 cells) through sili-
cone oil (described above) and the cell pellets were quantified for
nmol of [3H]dGlc. Km and Vmax values were derived from a linear
regression of a Lineweaver-Burk graph.
DNA probes for hybridization
The complete cDNA for rat erythroidlbrain hexose transporter,
GLUTI, was provided by J Vera (Memorial Sloan Kettering Cancer
Research Center, NY, USA). A 1.1-kb probe was generated by diges-
tion withNcoI. RatGLUT2 (prGLUT2), mouseGLUT3 (pmGLUT3-
6), rat GLUT4 (prGLUT4) and rat GLUT5 (prGLUT5-4) probes
were derived from glucose transporter cDNA clones kindly
supplied by Graeme Bell (Howard Hughes Medical Institute, The
University of Chicago, USA) (Bell et al, 1993). A P-actin DNA
probe (V Stanton, MIT, Cambridge, MA, USA) was used to assess
RNA loading. All probes were labelled in-gel with a random primer
labelling kit (Boerhinger-Mannheim, Indianapolis, IN, USA) to a
specific activity of 1-2 x 109 c.p.m. ,ug-' DNA.
RNA extraction and Northern hybridization
RNA was prepared by lysis of 1 x 108 logarithmically grown cells
with guanidine isothiocyanate and then centrifugation through a
caesium chloride cushion (Chirgwin et al, 1979). The RNA was
analysed by electrophoresis through 1% agarose gels after dena-
turing by treatment with formaldehyde. The RNA was transferred
by blotting to Gene-Screen Plus hybridization membranes (New
England Nuclear, Boston, MA, USA). Membranes were prehy-
bridized for 4 h and then hybridized overnight at 42°C in 50%
formamide, 5 x SSPE 7.5% dextran sulphate, I x Denhardt's solu-
tion, 1% sodium dodecyl sulphate (SDS) and 0.2 mg ml-' dena-
tured salmon sperm DNA. The blots were washed to a final
stringency of 0.2 x SSPE/0.1% SDS at 56-65°C before exposure
to Kodak XAR film at -70°C.
Membrane isolation
Membrane protein fractions from each subline were prepared as
previously described (Vera et al, 1991; Schurmann et al, 1992) with
some modifications. Cells (4 x 108) were washed twice in PBS and
resuspended into 5 ml oflysis buffer (20 mm Tris-Cl, pH 7.4, 1 mm
EDTA, 230 mm sucrose containing 20 ,ig ml-' aprotinin, 20 ,ug ml-'
leupeptin, 50 ,ug ml-' soybean trypsin inhibitor and 1 mM phenyl-
sulphonylfluoride) and homogenized on ice with a Dounce homog-
enizer. The homogenates were centrifuged at 1500 xg for 10 min at
4°C to pellet the nuclei. For total membranes, the resultant super-
natant was centrifuged at 150 000 xg for 90 min at 4°C to yield a
total membrane fraction, resuspended in lysis buffer and stored at
-70°C. For plasma membrane-enriched fraction, the supernatant
was centrifuged at 16 000 x g for 15 min at 4°C. The resulting
pellets were resuspended in lysis buffer, layered onto a 1.12 M
sucrose cushion (refractive index 1.3902, 38% w/v) and centri-
fuged for 70 min at 100 000 x g at 4°C. Plasma membranes were
collected from the interface between buffer and sucrose, resus-
pended in lysis buffer and stored at -70°C. Plasma membrane
protein was quantified by assaying the relative activity of alkaline
phosphodiesterase I using sodium thymidine 5'-monophosphate,p-
nitrophenyl ester (Sigma, St Louis, MO, USA) (Draye et al, 1987).
Analysis of GLUT1 and GLUT3 expression by Western
blotting
Plasma membrane protein samples were quantified using lyso-
zyme as a standard, reduced in Laemmli's buffer without boiling
(Asano et al, 1989) and resolved by electrophoresis (5 and 1 ,ug per
lane) on an 11% SDS-polyacrylamide minigel (Laemmli, 1970).
After electrophoresis, the gels were washed in Towbin's transfer
buffer (25 mM Tris, 192 mm glycine) with 20% methanol with
0.01% SDS. Samples were electroblotted overnight (30 V, 100
mA) at4°C to PVDF membranes (Immobolin P, 0.45gM pore size;
Millipore, Bedford, MA, USA). The membranes were blocked in
TBST [20 mm Tris, pH 7.6, 1% bovine serum albumin (BSA)
(w/v), 150 mm sodium chloride, 0.05% Tween-20] for 1 h at 25°C.
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After three washes in TBST, the membranes were probed with an
affinity-purified polyclonal antibody (East Acres Biologicals,
Southbridge, MA, USA) to the carboxy terminus of GLUT1
(Haspel et al, 1988) or GLUT3 (Nagamatsu et al, 1992) at a dilu-
tion of 1:5000 in TBST for 2 h at 25°C. After three washes in
TBST, the immunocomplexes were detected using ['251]protein A
at 0.01gCi ml-'; (117 mCi mg-' ICN) for 1 h at 25°C, washed in
TBST and air dried. Autoradiograms were analysed after exposure
to Kodak XAR film at -70°C and/or storage phosphor technology
(Phosphorlmager, Molecular Dynamics, Sunnyvale, CA, USA).
Molecular weight standards were electroblotted with samples.
Quantification of GLUT1 and GLUT3 in the plasma
membrane by immunodot blots
Plasma membrane protein samples were processed to Immobolin P
membranes pre-equilibrated in Towbin's buffer using a minifold
dot blot apparatus (Schleicher & Schuell, Keene, NH, USA).
Immobolin P (0.45-gM pore size) was determined by Western blot
analysis to retain a maximum of2.5 ,ug ofMEL plasma membrane
protein. Duplicate plasma membrane samples (serial dilutions from
0 to 2.5 gg) were adsorbed by dot blot to PVDF filter membranes
and washed in TE (pH 7.4). After Western blotting, the immuno-
complexes were detected with a 1:5000 dilution of GLUTI or
GLUT3 antisera as described above. The dot blots were quantified
by volume integration ofpixels/standard dotblot areausing storage
phosphortechnology (Molecular Dynamics, Sunnyvale, CA, USA)
(Johnston et al, 1990) and recorded as pixels jg- protein for each
cell line. The relative level ofexpression foreach isoform (GLUTI
or GLUT3) was normalized to the parental cell line.
Vincristine steady-state accumulation studies
VCR accumulation was assayed in 106 cells ml-' after 60 min incu-
bation in PBS using 25 nm [G-3H]vincristine sulphate (6.6-8.6
Ci mmol-'; Amersham, Arlington Heights, IL, USA) in a 37°C
shaking water bath. Steady-state VCR levels were achieved after
60 min ofincubation. Cell-associated radioactivity was determined
as described above. The data are expressed as a percentage ofcell-
associated [3H]VCR in parental cells from four separate experi-
ments each performed in triplicate. Surface binding at 4°C was
determined to be less than 1% ofthe total accumulation.
Effect of glucose transport inhibitors on steady-state
vincristine accumulation
Cells (1 x 106 ml-') were preincubated for 15 min at 37°C in
phloretin (PHL, 50 tM), cytochalasin B (CB, 6 gm; Sigma, StLouis,
MO, USA), cytochalasin E (CE, 6 gm; Sigma) or PBS (control)
before the addition of [G-3H]vincristine sulphate (25 nM) for 60
min drug accumulation studies (described above). The data are
expressed as a percentage of cell-associated [3H]VCR in parental
cells from four separate experiments each performed in triplicate.
The concentration ofCB used in these experiments was specific
for glucose transport inhibition and minimized other non-glucose
transport affinity binding and actin binding (Rampal et al, 1980).
CE has a low binding affinity for glucose transport proteins and
was used as a control to demonstrate a specific glucose transporter
binding by cytochalasin B (Vera et al, 1991). There was no solvent
effect on cell viability or VCR uptake with dimethyl sulphoxide
(DMSO) (0.08%, CB and CE).
Effect of phloretin on vincristine efflux
Approximately equimolar intracellular concentrations of VCR
were achieved in each subline (PC4-WT, PC-V40 and PC-V160)
at 1 x 106 cells ml-' in PBS by adding [G-3H]vincristine sulphate
(25 nM, 50 nm and 100 nm respectively during a 60 min incubation
in a 37°C shaking water bath. Cells were collected by centrifuga-
tion and resuspended to 1 x 106 cells ml-' in drug-free PBS at
37°C. At time zero, phloretin was added to a final concentration of
50 gM. Cells were incubated for 5 min at 37°C; VCR efflux has
been demonstrated to be linear for at least 5 min (Slapak et al,
1996). Residual cell-associated radioactivity was determined after
centrifugation through silicone oil as described above. There was
no solvent effect (0.2% ethanol) on VCR efflux.
Intracellular ATP levels
Cells were washed directly out of growth media. Employing a
luminescence determination (Bioluminescent Somatic Cell Assay
Kit, Sigma), duplicate tests with 5 x 104 cells were assayed and
light emission was measured by use of a liquid scintillation spec-
trophotometer (Beckman LS-235, Fullerton, CA, USA) (Stanley
and Williams, 1969).
Method for sequence comparisons
The translation of human MRP (GenBank/EMBL accession no.
L05628) (Cole et al, 1992), mouse MRP (amino acids 601-799; R
Deeley, personal communication), mouseGLUTI (GenBank/EMBL
accession no. M23384) (Kaestner et al, 1989) and mouse GLUT3
(GenBank/EMBL accession no. M75135) (Haspel et al, 1988)
sequences were analysed using the program Gap from the Sequence
Analysis Software Package of the Genetics Computer Group
(University Research Park, Madison, WI, USA) (Needleman and
Wunsch, 1970). A gap weight of 5.0 and length weight of0.3 were
used in the analyses.
Protein secondary structure predictions ofthe proposed cytocha-
lasin B binding site in human MRP (amino acids 686-710) (Cole
et al, 1992), mouse GLUTI (amino acids 388-412) (Kaestner et al,
1989) and mouse GLUT3 (amino acids 386-410) (Haspel et al,
1988) were performed using the MacVector program. Hydropathy
plots were graphed using the Kyte-Doolittle scale and a window
of seven amino acids (Kyte and Doolittle, 1982).
Statistical analyses
Paired t-tests were used to evaluate statistical significance in
drug accumulation studies, drug efflux studies, hexose transport
studies and Phosphorlmager calculations. Linear regression of
Lineweaver-Burk plots was used in the analysis of hexose trans-
port kinetic studies (Km and Vmax). All statistics were calculated
with software program Statview (Brainpower Inc., Calabasas, CA,
USA) and DeltaGraph 1.5 (Delta Point Inc., Monterey, CA, USA).
RESULTS
Steady-state glucose accumulation: effect of phloretin
The steady-state accumulation of glucose, as judged by accumula-
tion of[3H]dGlc, increased in cells withprogressive VCRresistance.
The PC-V40 subline accumulated 1.5-fold more and the PC-V160
subline accumulated twofold more [3H]dGlc than the parental cell
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Figure 1 Effect of phloretin on 2-deoxy-D-glucose (dGlc) accumulation in
parental and drug-resistant cell lines. Cells (1 x 106 mi-1) were preincubated
either in the presence of 100 gM phloretin/PBS or PBS alone for 15 min at
370C. A total of 50gM dGlc and 0.096 gM [3H]dGlc were added and the cells
were incubated for an additional 60 min. The reactions were terminated by
centrifugation through silicone oil and the uptake determined. The data are
expressed as a percentage of cell-associated [3H]dGlc in parental cells after
60 min of incubation. The average uptakes (± s.e.) from six experiments
each performed in duplicate are shown. *, control; *, phloretin (100 gM)
Table 1 Glucose transport kinetics
Kma Vmax (pmol dGlc min-' Relative index of
(mM) per 2 x 105 cells) glucose transportb
PC4-WT 1.49 ±.24 6.6 4.9 1
PC-V40 1.35 ±.46 12.5 1.8 1.9
PC-V160 1.45 ±.26 16.8 3.1 2.5
aValues are derived from a linear regression of a Lineweaver-Burk plot
(Figure 2). bThe Vmm, values were normalized to the parental cell line.
line (Figure 1). The transport of glucose was inhibited approxi-
mately 85-90% (P<0.05) by the competitive glucose transport
inhibitor, phloretin (100 gM) (Figure 1). As a competitive inhibitor
ofglucose transport, the effect ofphloretin differentiated facilitative
glucose transport from simple hexose diffusion (Krupka and Deves,
1980; Wheeler and Hinkle, 1985). These findings suggested that
dGlc, andtherefore glucose, uptake occurredprimarily viaafacilita-
tive glucose transporter(s) in the PC4 sublines.
Kinetic analysis of glucose transport
The kinetics of glucose transport were evaluated in the sublines
(Table 1 and Figure 2). Increases in V were observed: 1.9-fold
increase in PC-V40 and a 2.5-fold increase in the PC-V160 cell
line. The high correlation coefficients (r) calculated from the
linear regression of the glucose transport studies suggested unidi-
rectional glucose transport into the cells (Asano et al, 1989;
A PC4-WT
* PC-V40
* PC-V160
4 5
Figure 2 Kinetics of glucose transport in PC4 cell lines. A Lineweaver-Burk
plot of transport data is shown. Cells were washed once in PBS and
resuspended to 1 x 106 cells ml-' in PBS. dGlc was added to a final
concentration of 0.2-5.0 mm and 0.031 JM [3H]dGlc. Duplicate samples were
analysed for each dGlc concentration in three separate experiments at 370C
Colville et. al, 1993). The Km values (determined by [3H]dGlc
uptake) were within the reported range for mammalian erythroid
glucose transporter GLUTI (Asano et al, 1991, 1992) and for the
mammalian brain glucose transporter, GLUT3 (Asano et al, 1992;
Bell et al, 1993).
Analysis of GLUT expression by Northern hybridization
Total RNA from each subline was examined by Northern analysis
with rodent-specific cDNA probes for the GLUTI-5 transcripts.
Under high-stringency hybridization conditions, expression of
both GLUT1 and GLUT3 was detected in the parental and VCR-
selected sublines (Figure 3A). Expression ofGLUT2, GLUT4 and
GLUT5 was not detected even with prolonged film exposure. The
mRNA transcripts ofGLUT1 and GLUT3 were approximately 2.8
kb. The GLUT3 hybridized to a smaller transcript (2.8 kb) in these
erythroid cells than the size (4.0 kb) reported previously for
neuronal cells (Maheretal, 1992); however, a 2.7-kb transcript has
been noted in non-neuronal tissues (Yano et al, 1991). The level of
total GLUT mRNA in the parental cell line was reproducible at a
higher level than in the more resistant cell lines. Reprobing with
the 0-actin probe demonstrated near equal RNA sample loading.
Analysis of GLUTI and GLUT3 protein expression
The level ofGLUT protein found in total cell membranes mirrored
the pattern of GLUTI and GLUT3 RNA expression: somewhat
less protein was seen in the membranes from the PC-V40 and PC-
V160 sublines (data not shown). However, this pattern was not
seen in the Western blot analyses ofthe plasma membrane protein-
enriched preparations (Figure 3B). Here, instead, the level of
expression of broadly migrating polypeptides of Mr 47-51
(GLUTI) andMr48-52 (GLUT3) increased with VCR resistance.
Immunodot blots probed with GLUTI or GLUT3 antisera
provided additional quantitative analysis ofthe plasma membrane
GLUT protein content among these sublines. GLUT1 protein
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GLUTI
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expression was 40% higher in the plasma membranes from the
PC-V40 subline and threefold higher in those from the PC-V160
subline (Figure 3C). There was little change in the level ofGLUT3
protein expression in the PC-V40 cells, but a threefold increase
in the PC-V160 cells (Figure 3C). These findings paralleled the
relative increase in Vmax (Table 1) for glucose uptake in these
sublines. The equal activity of alkaline phosphodiesterase I, a
plasma membrane-associated enzyme, confirmed equal amounts
ofthe protein samples being tested.
AUXB1, a Chinese hamster ovarian cell line, a previously
reported (Maher et al, 1992) GLUT1-expressing, GLUT3-non-
expressing cell line provided positive and negative controls for the
antisera. Another separately derived MEL cell line, C7D (Slapak
et al, 1990), also demonstrated coexpression of GLUT1 and
GLUT3 with protein sizes equal to those seen in the PC4-WT cell
line (data not shown).
WT V40 V160
Effect of glucose transport inhibitors on vincristine
accumulation
Viso
3.3
± 0.53
3.0
± 0.04
GLUT1
GLUT3
GLUTI
The effect of glucose transport inhibitors (GTIs) on the 60-min
VCR accumulation in both non-P-gp- and P-gp-expressing MEL
cell lines was evaluated (Figure 4) in PBS without glucose to mini-
mize the interference of glucose with the binding by these
inhibitors.
Compared with the PC4-WT cells, the VCR accumulation in
PBS alone was reduced by 41% (P<0.05) in the PC-V40 subline
and 79% (P<0.05) in PC-V160 subline (Figure 4). These findings
were similar to the previous studies in the presence of glucose
(Slapak et al, 1996).
Pretreatment and incubation of the cell lines in 6 gM cytocha-
lasin B (CB), a competitive glucose transport inhibitor (Deves and
Krupka, 1978; Wheeler and Hinkle, 1985; Holman and Rees,
1987; Garcia et al, 1992), increased the steady-state VCR accumu-
lation in the PC-V40 cell line to the level of PC4-WT cells
(P<0.05) (Figure 4). In contrast, 6 gM cytochalasin E (CE), used
to assess any effects of cytochalasin independent of the glucose
transport inhibition, did not cause a statistically significant
GLUT3
140 -
Figure 3 Expression of GLUT1 and GLUT3 in parental and drug-resistant
cell lines. (A) Northern blots. RNA was isolated from parental PC4 (WT) and
PC-V40 and PC-V160 sublines. The RNA was resolved by electrophoresis
(20 gg per lane), transferred to a nylon membrane, then sequentially
hybridized with 32P-labelled cDNA probes for rat GLUT1, rat GLUT2, mouse
GLUT3, rat GLUT4 and rat GLUT5. A hybridization signal (corresponding to a
2.8-kb transcript) was detected only with the GLUT1 and GLUT3 probe.
Rehybridization with cDNA for 3-actin confirmed near-equal loading of lanes.
(B) Western blots. Plasma membrane protein samples (5 and 1 9g per lane)
from the parental, PC-V40 and PC-Vl60 cells were resolved by
electrophoresis on an 11% SDS-polyacrylamide gel. Western blotting was
performed with a GLUT1 or GLUT3 antisera at a dilution of 1:5000, and
immunocomplexes were detected with [1251]protein A and autoradiography.
Immunoblots detected broadly migrating polypeptides of M, 47-51 (GLUTI)
and Mr 48-52 (GLUT3). (C) Plasma membrane GLUT1 and GLUT3 protein
expression by immunodot blot. Plasma membrane samples were adsorbed
by dot blot to Immobolin P membranes. After transfer, Western blotting was
performed using GLUT1 or GLUT3 antisera. Immunocomplexes were
detected with [1251]protein A and quantified by volume integration of pixels per
standard dot blot area using storage phosphor technology (Johnston et al,
1990) and recorded as pixels g-1 protein for each cell line. Each value in the
table represents the mean and standard error from five protein dilutions
calculated as the ratio of subline to parental pixel values
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Figure 4 Effect of cytochalasin B and E on the accumulation of VCR in PC4
cell lines. PC4 cell lines (1 x 106 cells ml-') were preincubated in cytochalasin
B/PBS (6lM), cytochalasin E/PBS (6 gM) or control/PBS for 15 min at 370C.
[3H]VCR (25 nM) was added and cells were incubated for an additional 60
min at 370C. [3H]VCR uptake was determined as described in Figure 1.
Shown are the mean (± s.e.) of 3-4 separate experiments performed in
triplicate. *Significantly (P.0.05) increased intracellular [3H]VCR compared
with its own subline control
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Table 2 Effect of phloretin on vincristine efflux in PC4 cell lines
Loss of intracellular vincristinew (%)
Control Phloretin
PC4-WT 15 7
PC-V40 32 15b
PC-V160 46 41
aCells were incubated in [3H]VCR for 60 min in growth media without serum
at 370C at a concentration of [3H]VCR to obtain equimolar drug
concentrations: PC4-WT, 25 nM; PC-V40, 50 nM; PC-Vl60, 100 nm. Cells
were washed out of drug and resuspended in PBS with 50gM phloretin. After
5 min of incubation at 370C, the reaction was terminated by centrifugation
through silicone oil and cell-associated radioactivity was determined as
described in Figure 1. The % loss of initially accumulated vincristine by 5 min
is reported. bRepresents significantly (P.0.05) increased intracellular
[3H]VCR accumulation in PC-V40 with phloretin.
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Effect of phloretin on vincristine efflux
Increased vincristine efflux has been demonstrated in PC-V40 and
PC-V160 cells; efflux was linear for the first 5 min (Slapak et al,
1996). VCR efflux was evaluated in the presence of phloretin
(PHL). PHL diminished the VCR efflux rate in the PC-V40
subline to nearly that of the PC4-WT subline control (P<0.05)
(Table 2). This inhibitor had no significant effect on VCR efflux in
PC4-WT or PC-V160 cells.
Analysis of intracellular ATP content
ATP levels in cells grown in media was 4.1 x 10-'1 mol per cell +
0.90 (s.e.). There was no change in ATP content in the cell lines
after a total of 75 min incubation in either CB (6 tM)/PBS or CE
(6 JM)/PBS during steady-state VCR accumulation studies.
Sequence comparisons of the MRP, GLUT1 and GLUT3
proteins
- SLLSALLAEMDKVEGHV LKGSVAY - 710 MRP The gene sequences of human MRP (Cole et al, 1992), mouse
:. :
- WFIVAELFSQGPRPARIAVAGFSNW - 412 GLUTI GLUTI (Kaestner et al, 1989) and mouse GLUT3 (Haspel et al,
1988) were aligned using the GCG program, Gap. The overall
deduced proteins' percentage amino acid identities/similarities were
- SLLSALLAEMDKVEGHVTLKGSVAY - 710 MRP as follows: human MRP/mouse GLUTI, 12/35 (5 gaps); human
.:: :. .: :.: 1:..: MRP/mouse GLUT3, 15/43 (13 gaps); and mouse GLUT1/mouse
- WFIVAELFSQGPRPAAIAVAGCCNW -410 GLUT3 GLUT3, 64/80 (0 gaps). The murine MRP sequence has not yet
been reported, but we have learned that the deduced amino acid
sequence of murine and human MRP showed a greater than 90%
o- identity (RDeeley,personal communication).
o- ^ ^ Gap analyses (Figure SA) were also performed to determine the
° X _ possible presence of a CB-binding site in the MRP protein. Amino
o- t T t acids Trp-388-Trp-412 in mouse GLUTI and Trp-386-Trp-410 in
o- mouse GLUT3 are located within the putative CB-binding site
388 412 686 710 386 410 within the transmembrane 10-11 segments (Holman and Rees,
GLUT1 MRP GLUT3 1987; Garcia et al, 1992). These regions of GLUTI and GLUT3
were aligned with the Gap program to the human MRP protein
(Cole et al, 1992) revealing a corresponding region between the
i (A) Alignment of residues present in mouse GLUT1 and mouse Walker A and B motifs within the putative N-terminal ATP-
n the proximity of the proposed cytochalasin B-binding site to mouse binding domain (amino acids 686-710). From the deduced amino
be amino acids are presented as aligned by the GCG program Gap
rnan and Wunsch, 1970). Identical pairings are represented by lines acid sequence of this region of the mouse MRP (received from R
/ariable values of similarity are represented by dots (: or.). The Deeley), a 92-96% identity/similarity with human MRP was
sequences in mouse and human (not shown) MRP represent amino found. The percentage amino acid identities/similarities from these
6-710 and correspond to a region between the Walker A and B
ithin the N-terminal ATP-binding domain of the human MRP protein comparisons showed mouse MRP/mouse GLUTI, 12/44; mouse
al, 1992; R Deeley, personal communication). The amino acid MRP/mouse GLUT3, 12/44; and mouse GLUTl/mouse GLUT3,
:es Trp388-Trp4l2 in mouse GLUT1 and Trp386-Trp410 in mouse 88/92 0 F 5A are located within the transmembrane 10-11 segments. These ( gaps) (Figure ).
contain the putative CB-binding sites within the glucose transporters Other related gene sequences (Szczypka et al, 1994) were
and Rees, 1987; Garcia et al, 1992). The motif AxLxxxxxxxxxxxxxG aligned to the putative CB-binding domains on GLUT1 and
amino acid) was found within the mouse MRP (R Deeley, personal
iication), human MRP (Cole et al, 1992), mouse GLUT1 (Kaestner et GLUT3 using Gap: (1) mouse CFTR; (2) mouse P-glycoprotein
),mouse GLUT3 (Nagamatsu et al, 1992) and mouse GLUT4 (mdrl but not mdr3); (4) Leishmania P-gpA; (5) S. cerevisiae
)ret al, 1989) proteins. (B) Hydropathy plots of the proposed YCFI (yeast cadmium factor); and (6) human P-gp (MDRI). A asin B-binding site. The peptide sequences from mouse MRP
0), mouse GLUT1 (388-412) and mouse GLUT3 (386-410) were similar region of homology within the highly conserved
using the MacVector program with a Kyte-Doolittle scale and a nucleotide-binding regions to the GLUTI or GLUT3 CB-binding
of seven amino acids (Kyte and Doolittle, 1982) sites was not found in any but human P-gp. Here a region of
homology to the GLUT3 CB-binding site was noted within the N-
terminal ATP-binding fold; however, it did not correspond to the
1 of the [3H]VCR accumulation deficit in the PC-V40 cell same numerical residues nor did it have the 'conserved motif'
igure 4). Neither CB nor CE statistically increased VCR AxLxxxxxxxxxxAxxG. The hydropathy plots of mouse GLUTI,
ilation in PC4-WT or PC-V160 cells. The absence of an GLUT3 and MRP in this region demonstrated a similar pattern,
y CE suggested that CB's activity was linked to its affinity including two hydrophobic regions with an intervening short
glucose transporter (Rampal et al, 1980; Vera et al, 1991). hydrophilic region (Figure 5B).
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DISCUSSION
In multidrug-resistant murine erythroleukaemia cells, glucose
transport activity increased with increased drug resistance and was
associated with coexpression of two GLUT proteins, GLUTI and
GLUT3. Only GLUT1 is normally expressed in erythroid cells.
Mouse GLUTI has a widespread tissue distribution (Kahn and
Flier, 1990; Pessin and Bell, 1992; Bell et al, 1993) and was
expected in this murine erythroleukaemia cell line. Not expected
was the presence of the mouse GLUT3 isoform. These findings
indicated a less restricted tissue distribution for the GLUT3 isoform
than has previously been reported (Gould et al, 1992) and repre-
sented a novel murine (non-neuronal) GLUT3 tissue expression.
The GLUT1 and GLUT3 isoforms are primarily translocated
and expressed at the plasma membrane and regulate basal glucose
metabolism (Asano et al, 1992; Pessin and Bell, 1992; Schurmann
et al, 1992). The levels of GLUT1 and GLUT3 protein in the total
membrane ofthe cell lines correlated with the relative GLUT1 and
GLUT3 mRNA expression (Figure 4), but these levels did not
correlate with glucose transport. The PC-V40 expressed both a
reduced level of mRNA and total protein, but showed increased
glucose transport. This discrepancy was clarified by Western blot
analysis of the plasma membrane. There, the level of GLUT and
GLUT3 proteins correspondingly increased with the level of
glucose transport verifying the important location of the glucose
transporters.
The discordance between mRNA and protein levels and glucose
transport in the PC-V40 cell line may be caused by alterations in
metabolic state, in the stability or translatability of the mRNA or
the stability ofthe protein (Yamada et al, 1983; Haspel et al, 1986)
and could reflect an adaptive response to an increased energy
requirement associated with expression of mrp (PC-V40 subline)
or mdr3 (PC-V160 subline). In multidrug-resistant MEL cells, the
increased levels of glucose transport protein in the plasma
membrane paralleled the increased rates of vincristine efflux and
VCR resistance.
The possible participation of GLUTI in drug resistance was
previously suggested (Vera et al, 1991). CB and PHL, two inhibitors
of glucose transport, could overcome the reduced Vinca alkaloid,
vinblastine, accumulation conferred by the expression of rat
GLUT1 in Xenopus oocytes. In their drug-selected MDR cell line
expressing mdrl (the level of MRP was not evaluated in these cell
lines), CB was able to inhibit the outward transport of vinblastine.
However, in transfected oocytes expressing P-gp, this GTI effect
was not demonstrated.
In vincristine-selected PC4 cell lines, murine MRP was
expressed primarily in the plasma membrane (Slapak et al, 1996).
The MRP-overexpressing cell line, PC-V40, was capable of an
energy-dependent outward efflux of VCR, independent of P-
glycoprotein. The cell line PC-V160 demonstrated a greater rate of
VCR efflux with coexpression of MRP and P-gp. However,
compared with the PC-V40 cell line, PC-V160's level ofMRP was
significantly less. A possible association between MRP and/or P-
gp function and plasma membrane-associated GLUT protein
expression was evaluated by the effect of GTIs on VCR transport
in the cell lines, all ofwhich coexpressed GLUT1 and GLUT3. CB
reversed the deceased VCR accumulation in PC-V40, the cell line
that overexpressed MRP. No such CB effect was seen in the PC-
V160 cell line, which overexpressed both MRP and P-gp. CE at
the same concentration did not affect the accumulation of VCR in
any of the cell lines. Since CE has an approximately 20-fold
greater incorporation into actin-binding sites than CB, our results
indicate that neither CB nor CE at these concentrations affected
actin and presumably the intracellular cytoskeletal function.
Anotherinhibitor, PHL, reduced the rate ofVCR efflux in PC-V40
to the level ofthe parental cell line. In contrast, PHL did not affect
VCR efflux in the PC-V160 cell line or parental cell line. More
recent studies have shown that indomethacin, a specific inhibitor
of MRP, affected VCR resistance in PC-V40, but not VCR resis-
tance in PC-V160 (Draper et al, submitted). Taken together these
data suggest that VCR efflux was primarily associated with MRP
overexpression in the PC-V40 cell line and with P-glycoprotein
overexpression in the PC-V160 cell line.
CB has been demonstrated to inhibit glucose transport competi-
tively in erythrocytes (Deves and Krupka, 1978). It may bind at or
near the inward-facing glucose-binding site of GLUTI in the
region of Trp-388 to Trp-412 within the transmembrane segment
10-1l (Garcia et al, 1992). The amino acid sequences representing
the putative CB-binding domain in the GLUT1 and GLUT3
proteins were compared with the protein sequence of the MRP
protein (Cole et al, 1992). A single polypeptide sequence located
between the Walker A and B motifs within the putative N-terminal
ATP-binding cassette domain ofhuman MRP showed similarity to
the CB-binding site located within the transmembrane 10-11
segments of the GLUT1 and GLUT3 proteins (Figure 5 legend).
The similar hydropathy patterns in these regions suggested
possible structural similarities in this sequence among these
proteins (Figure 5). The binding domain of phloretin on glucose
transport proteins is not well characterized (Krupka and Deves,
1980; Wheeler and Hinkle, 1985).
The results suggest that CB and PHL block a putative VCR
efflux protein, e.g. MRP, or act directly on one or both GLUT
proteins, which themselves are somehow associated with drug
efflux. It is possible that glucose transporters could in some
manner modulate MRP's ability to transport VCR out of the cell.
That energy reserves (ATP) were not depleted during the transport
inhibition studies indicated that intracellular energy depletion was
not responsible for the GTI's effect on VCR efflux in PC-V40
cells. Understanding the mode of action of GTIs on MRP-medi-
ated resistance may help us understand MRP function better, as
well as the possible role ofGLUT proteins in MRP activity.
ABBREVIATIONS
MRP, multidrug resistance-associated protein; P-gp, P-glycopro-
tein; GLUT1, type 1 isoform ofthe facilitative glucose transporter;
GLUT3, type 3 isoform of the facilitative glucose transporter;
VCR, vincristine; MDR, multidrug resistance; dGlc, 2-deoxy-D-
glucose; PBS, phosphate-buffered saline; PHL, phloretin; CB,
cytochalasin B; CE, cytochalasin E.
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